Evidence map›Paper›PMID 36532023›Full record

ArticleFrontiers in immunology2022

ADAR1 promotes systemic sclerosis

Chenming Sun, Dunpeng Cai, Shi-You Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Chenming SunDepartment of Pathogenic Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Dunpeng CaiDepartments of Surgery, University of Missouri School of Medicine, Columbia, MO, United States.
Shi-You ChenDepartments of Surgery, University of Missouri School of Medicine, Columbia, MO, United States.
University of Missouri · USXi'an Jiaotong University · CN

Funding

Novel mechanism of smooth muscle phenotypic modulation and vascular remodelingR01HL119053 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHEN, SHIYOU · 2014 to 2023
$3.8M
Dedicator of cytokinesis 2 in abdominal aortic aneurysmR01HL147313 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CHEN, SHIYOU · 2019 to 2022
$2.1M
NHLBI NIH HHS R01 HL119053NHLBI NIH HHS R01 HL147313
6 · The paper itself

Abstract

Introduction: As a multisystem autoimmune disorder disease, systemic sclerosis (SSc) is characterized by inflammation and fibrosis in the skin and other internal organs. However, mechanisms underlying the inflammatory response that drives the development of SSc remain largely unknown. Methods: ADAR1 heterozygous knockout (AD1+/-) mice and myeloid-specific ADAR1 knockout mice were used to determine the function of ADAR1 in SSc. Histopathological analyses and western blot confirmed the role of ADAR1 in bleomycin-induced increased skin and lung fibrosis. Results: In this study, we discover that adenosine deaminase acting on RNA (ADAR1), a deaminase converting adenosine to inosine (i.e., RNA editing) in RNA, is abundantly expressed in macrophages in the early stage of bleomycin-induced SSc. Importantly, ADAR1 is essential for SSc formation and indispensable for classical macrophage activation because ADAR1 deficiency in macrophages significantly ameliorates skin and lung sclerosis and inhibits the expression of inflammation mediator inducible NO synthase (iNOS) and IL-1β in macrophages. Mechanistically, deletion of ADAR1 blocks macrophage activation through diminishing NF-κB signaling. Discussion: Our studies reveal that ADAR1 promotes macrophage activation in the onset of SSc. Thus, targeting ADAR1 could be a potential novel therapeutic strategy for treating sclerosis formation.

Indexed as

Macrophage ActivationScleroderma, SystemicAdenosine DeaminaseAnimalsBleomycinMiceMice, KnockoutRNASclerosisADAR1 protein, mouseAdenosine DeaminaseBleomycinRNAADAR1IL-1βmacrophage activationNF-κBsystemic sclerosis

Identifiers

PMID36532023
PMCPMC9751044
OpenAlexW4310490723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.